O ne of the safe and non-invasive methods for in-vivo imaging and clinical diagnosis is magnetic resonance imaging (MRI) that acquires images without applying ionizing radiation. Inherent contrast in MRI depends on T1 and T2 relaxation times, and proton density of the materials or tissues [1] . In the cases that the diseased and normal tissues have similar composition, MRI inherent contrast is not sufficient to differentiate the pathologic and normal tissues. Therefore, the use of contrast agents that enhance MRI contrast is essential [2] . MRI contrast agents consist of paramagnetic or superparamagnetic metal ions which reduce the proton relaxation times and therefore produce signal intensity changes in the accumulated region [3] . This signal changes are seen on the MR images as bright regions using positive contrast agents and dark regions by applying negative contrast media [2] . The ability of a contrast agent to improve MR image contrast is determined by relaxivity which shows the changes of the relaxation rates (1/T1 or 1/T2) of the Original ABSTRACT Background: Magnetic resonance imaging (MRI) contrast agents have an
Introduction
O ne of the safe and non-invasive methods for in-vivo imaging and clinical diagnosis is magnetic resonance imaging (MRI) that acquires images without applying ionizing radiation. Inherent contrast in MRI depends on T1 and T2 relaxation times, and proton density of the materials or tissues [1] . In the cases that the diseased and normal tissues have similar composition, MRI inherent contrast is not sufficient to differentiate the pathologic and normal tissues. Therefore, the use of contrast agents that enhance MRI contrast is essential [2] . MRI contrast agents consist of paramagnetic or superparamagnetic metal ions which reduce the proton relaxation times and therefore produce signal intensity changes in the accumulated region [3] . This signal changes are seen on the MR images as bright regions using positive contrast agents and dark regions by applying negative contrast media [2] . The ability of a contrast agent to improve MR image contrast is determined by relaxivity which shows the changes of the relaxation rates (1/T1 or 1/T2) of the Although traditional gadolinium chelates are usually used as paramagnetic positive contrast agents for MRI, iron oxide nanoparticles have been used as both negative and positive contrast media [4] [5] [6] . The nanoparticles advantages are including large magnetic moment, superparamagnetic behavior, metabolizable nature and high dipolar relaxivity [7] . The nanoparticles are usually coated with a biocompatible material to decrease the cytotoxicity of bare iron oxide [8] , provide chemical stability and prevent aggregation of the nanoparticles from large clusters [9] . Different coating materials have been investigated for these purposes such as dextran and polyethylene glycol [10] .
Zeolites are aluminosilicate crystalline materials with a regular, microporous structure containing the pores in molecular dimensions (0.3 to 1 nm) and having different amounts of Si/Al ratio [11] [12] [13] [14] [15] . Pore structures and crystal size are critical factors in determining the properties, for example 4A zeolite is one of the synthetic zeolites with very small pore of 4 Å. The use of zeolite as a carrier of paramagnetic metal ions has been investigated. In a study, gadolinium zeolite has been used for gastrointestinal tract MR imaging [16] . In another study, Norek et al. reported Gd 3+ -loaded NaY zeolite potential to use as MRI contrast agent [17] . Despite iron oxide nanoparticles advantages, studies on the combination of iron oxide nanoparticles and 4A zeolite as MRI contrast agent have not been done.
The aim of this study was to evaluate the ability of iron oxide-4A (F4A) nanocomposite as MRI contrast agent. For this purpose, iron oxide nanoparticles were synthesized and encapsulated in the 4A nanozeolite pores by the hydrothermal method and magnetic resonance properties of the F4A nanocomposite were investigated.
Material and Methods

Synthesis and Characterization of
Magnetic F4A Nanocomposite 3.12 g NaOH was added to 45 ml water and stirred, then 2.62 g Al 2 O 3 and 2.5 g sodium silicate were added and stirred for 7 hours. The proper amount of nano Fe 3 O 4 (1.7%) was added to the produced gel. The mixture was carried out in an oven at 80 °C for 8 hours and washed, then dried.
X-ray diffraction (XRD) and scanning electron microscopy (SEM) were used for the nanocomposite characterization.
MTT Assay for Cell Viability
MCF7 cells (15×10 3 cells for each well) were cultured in 96-well plates with 200 μL of media in each well at 37°C. After an incubation time (24 hours), the used media were removed and the wells were washed with phosphatebuffered solution (PBS). To measure the rate of cellular proliferation, 50 μL of MTT (3-(4, 5-dimetylthiazol-2-yl)-2, 5-diphenyl-trazolium bromide) and 150 μL culture medium were added to each well. The cells were incubated at 37°C and 5% CO 2 for 24 hours. Then the media were removed, and 200 μL of dimethyl sulfoxide and 25μL Sorenson buffer were added to each well. Finally, absorbance was read using an ELISA plate reader at 570 nm wavelength.
MRI Study
For MRI study, suspensions of F4A with different Fe concentrations of 0.0084, 0.0140, 0.0219 and 0.0284 mM were prepared by ultrasonic method. MR imaging of the samples was carried out in a 1.5 Tesla clinical MRI scanner (Magnetom Avanto, Siemens Healthcare, Germany). All glass tubes containing F4A samples were placed in the water-containing plastic container.
T1 relaxation time measurement was carried out using spin echo (SE) pulse sequence with repetition time (TR) values of 250, 500, 1000, 2000, and 4000 ms and a fixed echo time (TE) of 11 ms. T2 relaxation times were determined using a T2-weighted multi-echo spin-echo se-
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Iron Oxide-4A as MRI Contrast Agent quence with a fix TR of 3000 ms and four TE values of 13, 26, 39 and 52 ms. All the images were acquired by a slice thickness of 5 mm, a field of view (FOV) of 160×160 mm 2 , and a matrix of 256×196 pixels.
Data analysis was carried out using DicomWorks program. Regions of interest (ROIs) were selected in each test tube image and signal intensities of the F4A samples were obtained. R1 (1/T1) and R2 (1/T2) relaxation rate values were calculated from the nonlinear fit of the mean signal intensity versus TR and TE, respectively. The T1 and T2 relaxivities were obtained from the slope of the linear fit of the R1 and R2 relaxation rates versus Fe concentration of the F4A nanocomposite, respectively.
Results
Characterization of Magnetic F4A Nanocomposite Figure 1 shows the XRD patterns of F4A nanocomposite. As shown in figure, only characteristic peaks of F4A were observed and no other structures of initial materials were present.
SEM of F4A is shown in Figure 2 , there (P ˃ 0.05). The differences between controls and the range of the nanocomposite concentrations were not significant which showed the F4A is not toxic to the MCF7 cell line.
MRI Study
Exponential recovery of signal with TR increasing in the all T1 curves, and exponential Cytotoxicity of F4A Nanocomposite Figure 3 shows the effect of increasing amounts of the F4A nanocomposite on the cells viability determined by the MTT assay According to Figure 4 , a linear correlation was observed between R1 and R2 relaxation rates with Fe concentration. The mean slopes (T1 and T2 relaxivities) were 5.413 and 1092.1 mM -1 .s -1 , respectively which led to the T2/T1 relaxivity ratio of 201.75.
Discussion
Characterization of F4A Nanocomposite XRD analysis results (Figure 1 ) indicated that the F4A nanocomposite was successfully synthesized. SEM image (Figure 2 ) confirmed the nanosize and structural uniformity of the nanocomposite.
MRI Study
The results indicate that although iron oxide nanoparticles in nanocomposite structure have effects on both T1 and T2 relaxation times shortening, T2 shortening effect is dominant. Iron oxide nanoparticles produce large local magnetic fields and accelerate spin dephasing of water protons. Therefore, the high T2-shortening effect results.
Similarly, as Figure 4 illustrates, T2 relaxivity of the F4A is higher than T1 relaxivity. High T2 relaxivity of the nanocomposite resulted from two main reasons; first, its structural pores and channels, and second, low ratio of Si/Al which gives hydrophilic property to the 4A zeolite. As it seen in Figure 5 , iron oxide sub-nanoclusters are capsulated in the pores and channels of the 4A zeolite and therefore they have enough access to water protons in pores and channels (positions 1 & 2) of 4A zeolite. This situation enhances spin dephasing of the protons and reduces T2 relaxation time. Therefore, subsequently increasing of T2 relaxivity is resulted. It is noted that due to low concentration of iron oxide nanoparticles in nanocomposite structure, they are only placed in pores and channels, not on the surface of the zeolite (position 3).
The relaxivity ratio determines the effi- ciency of a contrast agent as an MRI T1 or T2 agent. If T2/T1 relaxivity ratio is much bigger than 1, the contrast agent will be described as a T2 agent while in T1 contrast agents, the ratio is closed to 1 [18] . The high T2/T1 relaxivity ratio of F4A confirms that the nanocomposite can act as an MRI T2 contrast agent. The T2/T1 relaxivity ratio of F4A is significantly higher than iron oxide nanoparticles coated with organic materials in other studies. For example, the relaxivity ratio for dextran, carboxymethyl dextran (CMD), PEG-dextran [10] , PEG [19] and carboxydextran [20] coated iron oxide nanoparticles were respectively reported 29.23, 11.23, 23.71, 5.7 and 9.5 in other studies which are much lower than that of F4A. Although these differences resulted from the different sizes of the iron oxide nanoparticles, and the types and thicknesses of coating materials in the studies, the 4A zeolite special structure consists of pores and channels has an im portant role in high relaxivity ratio of the F4A due to its enough water accessibility.
Conclusion
New contrast agents designed for the optimal use of MRI are necessary. Therefore, in the current study, new zeolite based MRI contrast agent (iron oxide-4A (F4A) nanocomposite) was successfully synthesized by using the hydrothermal method. Then the ability of the F4A to use as an MRI contrast agent was investigated by the use of 1.5 Tesla clinical MRI. The results demonstrate that our nanocomposite is suitable to act as a T2 contrast agent due to its large T2/T1 relaxivity ratio at clinical field strength.
